{"id":"aripiprazole-augmentation","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Akathisia"},{"rate":"5-15","effect":"Weight gain"},{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Sedation"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2219425","moleculeType":"Small molecule","molecularWeight":"660.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole is added to existing antidepressant therapy to potentiate antidepressant effects through dopaminergic and serotonergic modulation. As a partial D2 agonist, it can stabilize dopamine signaling, while its 5-HT1A partial agonist activity complements SSRI/SNRI mechanisms. This augmentation strategy is particularly used in patients with inadequate response to antidepressants alone.","oneSentence":"Aripiprazole augmentation enhances the efficacy of antidepressants by acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, improving mood regulation in treatment-resistant depression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:27:37.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Augmentation therapy for major depressive disorder in patients with inadequate response to antidepressants"},{"name":"Treatment-resistant depression"}]},"trialDetails":[{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT07011693","phase":"PHASE4","title":"Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)","status":"NOT_YET_RECRUITING","sponsor":"Xinyu Zhou","startDate":"2025-06-20","conditions":"Major Depressive Disorder (MDD)","enrollment":400},{"nctId":"NCT04539951","phase":"PHASE2","title":"Pragmatic Trial of Obsessive-compulsive Disorder","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2020-09-22","conditions":"Obsessive-Compulsive Disorder","enrollment":1600},{"nctId":"NCT02752542","phase":"PHASE4","title":"Personalized Indications for CBT and Antidepressants in Treating Depression","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2016-10-31","conditions":"Major Depressive Disorder, Persistent Depressive Disorder","enrollment":80},{"nctId":"NCT05531591","phase":"PHASE4","title":"RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2019-08-01","conditions":"Depression, Dementia, Mild Cognitive Impairment","enrollment":87},{"nctId":"NCT02960763","phase":"PHASE4","title":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-02-24","conditions":"Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression","enrollment":742},{"nctId":"NCT06467474","phase":"NA","title":"Psychoeducational Group for Depression","status":"RECRUITING","sponsor":"Ricardo Alberto Moreno, M.D., Ph.D.","startDate":"2024-03-01","conditions":"Major Depressive Disorder (MDD","enrollment":338},{"nctId":"NCT06054321","phase":"NA","title":"Psychopharmacotherapy for Depressive Patients","status":"RECRUITING","sponsor":"Chonnam National University Hospital","startDate":"2022-08-03","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT00276978","phase":"PHASE3","title":"Aripiprazole Augmentation Therapy in Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"University Hospital Freiburg","startDate":"2005-06","conditions":"Therapy-resistant Depression","enrollment":""},{"nctId":"NCT02977299","phase":"PHASE4","title":"Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-05-01","conditions":"Treatment Resistant Major Depressive Disorder","enrollment":278},{"nctId":"NCT00279409","phase":"PHASE2","title":"Treatment of Children With ADHD Who do Not Fully Respond to Stimulants","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2006-07","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":10},{"nctId":"NCT01942187","phase":"PHASE4","title":"A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2013-08","conditions":"Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder Not Otherwise Specified (NOS)","enrollment":""},{"nctId":"NCT01421342","phase":"PHASE3","title":"VA Augmentation and Switching Treatments for Improving Depression Outcomes","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-12","conditions":"Major Depressive Disorder","enrollment":1522},{"nctId":"NCT00953745","phase":"NA","title":"Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":43},{"nctId":"NCT00220636","phase":"PHASE4","title":"Abilify as an Adjunctive Treatment for Refractory Depression","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2005-03","conditions":"Depressive Disorder, Major","enrollment":15},{"nctId":"NCT01386086","phase":"PHASE3","title":"Aripiprazole and Resistant Postpartum Depression","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2011-06","conditions":"Postpartum Depression","enrollment":10},{"nctId":"NCT00892047","phase":"PHASE4","title":"Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2009-08","conditions":"Depression","enrollment":468},{"nctId":"NCT00489866","phase":"PHASE2","title":"Aripiprazole Augmentation of Antidepressants in PTSD","status":"COMPLETED","sponsor":"Durham VA Medical Center","startDate":"2007-03","conditions":"PTSD","enrollment":14},{"nctId":"NCT00194038","phase":"PHASE4","title":"Aripiprazole in Late Life Bipolar Disorder","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2004-04","conditions":"Bipolar Disorder","enrollment":20},{"nctId":"NCT01429831","phase":"PHASE4","title":"Aripiprazole for the Augmentation of Antidepressant Therapy","status":"COMPLETED","sponsor":"Taiwan Otsuka Pharm. Co., Ltd","startDate":"2011-09","conditions":"Major Depressive Disorder","enrollment":300},{"nctId":"NCT00608543","phase":"PHASE4","title":"Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2005-10","conditions":"Major Depressive Disorder","enrollment":17},{"nctId":"NCT01488266","phase":"NA","title":"Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder","status":"UNKNOWN","sponsor":"Korea University","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":90},{"nctId":"NCT00328367","phase":"PHASE4","title":"Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2005-12","conditions":"Schizophrenia","enrollment":61},{"nctId":"NCT00174876","phase":"PHASE2","title":"Aripiprazole as Augmentation for TRD","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2004-07","conditions":"Depression","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":167,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Abilify"],"phase":"marketed","status":"active","brandName":"Aripiprazole Augmentation","genericName":"Aripiprazole Augmentation","companyName":"Centre for Addiction and Mental Health","companyId":"centre-for-addiction-and-mental-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole augmentation enhances the efficacy of antidepressants by acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, improving mood regulation in treatment-resistant depression. Used for Augmentation therapy for major depressive disorder in patients with inadequate response to antidepressants, Treatment-resistant depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}